Geneva Capital Management LLC decreased its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 11.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,249,396 shares of the medical device company’s stock after selling 167,671 shares during the period. Globus Medical makes up 2.6% of Geneva Capital Management LLC’s investment portfolio, making the stock its 11th largest holding. Geneva Capital Management LLC owned approximately 0.93% of Globus Medical worth $93,580,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Phoenix Financial Ltd. raised its stake in Globus Medical by 131.8% in the third quarter. Phoenix Financial Ltd. now owns 9,967 shares of the medical device company’s stock worth $749,000 after buying an additional 5,667 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Globus Medical by 12.6% in the third quarter. William Blair Investment Management LLC now owns 1,447,365 shares of the medical device company’s stock worth $108,408,000 after buying an additional 162,469 shares during the period. Allworth Financial LP lifted its holdings in Globus Medical by 3.5% in the third quarter. Allworth Financial LP now owns 12,797 shares of the medical device company’s stock worth $1,011,000 after buying an additional 436 shares during the period. Russell Investments Group Ltd. boosted its position in Globus Medical by 335.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 143,614 shares of the medical device company’s stock valued at $10,758,000 after acquiring an additional 110,602 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its position in Globus Medical by 14.7% during the 3rd quarter. Maryland State Retirement & Pension System now owns 6,743 shares of the medical device company’s stock valued at $505,000 after acquiring an additional 863 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.
Globus Medical Price Performance
Shares of NYSE GMED opened at $72.02 on Monday. Globus Medical, Inc. has a 1 year low of $70.39 and a 1 year high of $101.40. The firm has a 50-day moving average of $76.56 and a 200 day moving average of $82.71. The stock has a market cap of $9.54 billion, a P/E ratio of 17.69, a price-to-earnings-growth ratio of 1.12 and a beta of 0.98.
Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business’s revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Research analysts expect that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Ann Rhoads sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the sale, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. The trade was a 12.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James R. Tobin sold 41,666 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at approximately $1,127,400. This represents a 73.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 101,666 shares of company stock worth $7,970,017. Insiders own 18.38% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. UBS Group initiated coverage on Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price on the stock. Canaccord Genuity Group lowered their target price on Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, November 6th. BMO Capital Markets lowered Globus Medical from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $94.00 to $78.00 in a research report on Friday, November 6th. Royal Bank Of Canada reduced their price target on Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, October 1st. Finally, Wells Fargo & Company upped their price target on Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.08.
Get Our Latest Analysis on Globus Medical
Globus Medical Profile
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Featured Stories
- Five stocks we like better than Globus Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
